CLOCK-Binding Small Molecule for Selective BMAL1 Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a scarcity of potent and selective inhibitors of CLOCK:BMAL1 interaction, which are effective in treating and/or preventing circadian rhythm-related disorders such as aging, sleep disorders, and metabolic diseases.
Innovation Solution
A novel CLOCK-binding compound, named CLK8, is developed to inhibit the interaction between CLOCK and BMAL1 by binding to the CLOCK protein, specifically to the hollow between the α2 helix of the bHLH domain and the HB strand of the PAS-A domain, thereby reducing nuclear translocation of CLOCK and enhancing circadian rhythm amplitude.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If small molecules are used to modulate circadian rhythm, then reversible and time/dose-tunable effects are achieved, but there is a scarcity of potent and selective inhibitors of CLOCK:BMAL1 interaction
Solution Approach 1:
The compound CLK8 is designed to bind specifically to a localized region on the CLOCK protein, namely the hollow between the α2 helix of the bHLH domain and the HB strand of the PAS-A domain. This localized binding approach enables selective inhibition of CLOCK:BMAL1 interaction without affecting other circadian clock components, thereby achieving high selectivity while addressing the scarcity of potent inhibitors.
Solution Approach 2:
CLK8 acts as an intermediary small molecule that mediates the inhibition of CLOCK:BMAL1 interaction. By binding to CLOCK and sterically blocking the interaction interface, CLK8 serves as a molecular mediator that reversibly prevents the formation of the CLOCK:BMAL1 heterodimer, enabling time- and dose-tunable control of circadian rhythm with high selectivity.
2Reliability
If CLOCK:BMAL1 interaction is inhibited to treat circadian disorders, then therapeutic benefits are achieved, but the complexity of targeting protein-protein interaction increases
Solution Approach 1:
The invention extracts and targets a specific, accessible region on the CLOCK protein surface - the hollow between the α2 helix and HB strand - as the binding site for inhibition. By focusing on this extracted local feature rather than attempting to disrupt the entire CLOCK:BMAL1 interface, the design simplifies the molecular complexity while maintaining therapeutic efficacy through selective blockade of the interaction.
Solution Approach 2:
The compound CLK8 utilizes specific molecular parameters including its chemical structure with key functional groups positioned to fit the hollow region of CLOCK. The binding affinity and selectivity are optimized by adjusting parameters such as molecular size, shape complementarity, and chemical interactions (hydrogen bonding, hydrophobic interactions) within the binding site, thereby achieving effective inhibition without excessive molecular complexity.
Data Source
AI summary
A 2-[2-({12,12-dimethyl-4-oxo-6-phenyl-3,11-dioxatricyclo[8.4.0.0,2,7]tetradeca-1,5,7,9-tetraen-8-yl}oxy)acetamido]benzamide compound and related derivatives, as well as the use thereof in the preparation of a medicament for treatment and/or prevention of diseases or disorders associated with the circadian rhythm are provided. The compound of the invention is a CLOCK-binding small molecule and also an inhibitor of CLOCK:BMAL1 interaction, and is therefore useful, as pharmaceutical agent, especially in the treatment and/or prevention of disorders associated with the circadian rhythm.